Last updated 2 months ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.
The numbers are staggering. In 2022, the United States reported 81,806 opioid-involved overdose deaths, the highest number in any previous year. These fatalities represent lives lost to a crisis that continues to devastate families and communities across America.
Against this backdrop of loss, federal health agencies have rallied behind a single, evidence-based strategy: Medication-Assisted Treatment, known as MAT. The Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Disease Control and Prevention (CDC), and National Institute on Drug Abuse (NIDA) all endorse MAT as the “gold standard” for treating opioid use disorder.
MAT reduces overdose deaths by at least 50% compared to no treatment. It keeps people in recovery programs longer, reduces criminal activity, and saves society money. Yet despite this track record, only about 25% of Americans who need this treatment actually receive it.
What is Medication-Assisted Treatment?
Medication-Assisted Treatment combines FDA-approved medications with counseling and behavioral therapies to provide what experts call a “whole-patient” approach to substance use disorders. While most discussions focus on opioid use disorder, MAT also effectively treats alcohol use disorder.
The philosophy behind MAT recognizes addiction as a complex, chronic brain disease that requires comprehensive treatment. The medication component targets the physical aspects of addiction by normalizing brain chemistry, blocking euphoric effects, and relieving cravings. This physiological stabilization allows people to engage more fully in counseling and behavioral therapy.
Think of it like treating diabetes. A person with diabetes needs insulin to manage their blood sugar, but they also need lifestyle changes, dietary counseling, and regular medical monitoring. MAT works similarly—the medication manages the brain chemistry disrupted by addiction while therapy addresses the psychological and social factors.
The Language Shift: MAT to MOUD
Medical professionals increasingly use the term “Medications for Opioid Use Disorder” (MOUD) instead of MAT. This change reflects a deeper shift in understanding addiction. The original term “assisted” subtly suggested medication was secondary to other treatments, potentially reinforcing the harmful idea that it’s merely a “crutch.”
MOUD places medications on equal footing with other first-line medical treatments for chronic diseases. This reframing challenges moralistic views of addiction and reinforces the modern understanding of opioid use disorder as a treatable medical condition.
The language change has policy implications too. It strengthens arguments for low-barrier access models where the priority is delivering life-saving medication quickly, rather than requiring extensive counseling before treatment begins.
Why Experts Call MAT the Gold Standard
Federal agencies didn’t choose the “gold standard” designation lightly. Decades of research demonstrate MAT’s effectiveness across multiple critical outcomes that matter most: saving lives, keeping people in treatment, and improving public health.
Dramatic Reduction in Deaths
The most compelling evidence comes from mortality studies. Multiple large-scale research projects show people with opioid use disorder who receive methadone or buprenorphine are at least 50% less likely to die from overdose compared to those who receive no treatment.
A 2023 Yale study found methadone reduced fatal overdose risk by 38% and buprenorphine by 34% compared to no treatment. The life-saving benefits extend beyond overdoses—retention in both methadone and buprenorphine treatment is associated with substantial reductions in all-cause mortality.
The evidence becomes even more striking when compared to alternatives. Opioid use creates high physiological tolerance, meaning users need increasingly larger doses to achieve the same effect. Detoxification successfully removes opioids from the body but also eliminates this tolerance.
When people relapse after detox-only programs—which happens frequently—they face enormous risk. Their previous dose, once manageable, can now be lethal. The Yale study found that non-medication treatments actually increased death risk by over 77% compared to no treatment at all.
This research fundamentally reframes MAT’s “gold standard” status. It’s not just effective—the primary alternative is demonstrably dangerous.
Breaking the Addiction Cycle
MAT medications work by stabilizing brain chemistry and relieving the intense cravings that drive compulsive drug use. By normalizing the brain circuits disrupted by addiction, the medications allow people to stop the exhausting daily pursuit of illicit drugs.
Studies consistently show MAT significantly decreases or eliminates illicit opioid use. Patients in MAT programs are also far more likely to stay in treatment—one of the most important predictors of long-term success.
Research shows treatment durations under 90 days are rarely associated with positive outcomes, making retention critical for recovery.
Broad Public Health Benefits
MAT’s positive impacts extend far beyond individual patients to entire communities.
Disease Prevention: By reducing injection drug use and needle sharing, MAT decreases transmission of HIV and Hepatitis C. This public health benefit protects both users and the broader community.
Crime Reduction: Multiple studies associate MAT with significant decreases in criminal activity. When physical compulsion to use drugs is managed, the need to commit crimes to fund addiction often disappears.
Correctional Benefits: The benefits are particularly dramatic for incarcerated individuals. Providing MAT in jails and prisons reduces recidivism and dramatically lowers fatal overdose rates after release. A landmark Rhode Island study found implementing comprehensive MAT led to a 60.5% reduction in post-release overdose deaths.
Economic Impact
The financial benefits are staggering. One analysis found that for every dollar spent on methadone maintenance therapy, society saves nearly $38 in lifetime costs related to healthcare, criminal justice, and lost productivity.
Another study found MAT yielded lifetime savings of $25,000 to $105,000 per person treated when criminal justice costs were included. These aren’t just academic calculations—they represent real money saved by taxpayers and society.
The Three MAT Medications for Opioid Use Disorder
Three FDA-approved medications form the backbone of MAT for opioid use disorder: methadone, buprenorphine, and naltrexone. These drugs work by interacting with the same brain receptors targeted by opioids like heroin and fentanyl, but in distinctly different ways.
While all three are FDA-approved and effective, they’re not clinically interchangeable. A clear hierarchy of evidence exists, with the “gold standard” designation most strongly associated with methadone and buprenorphine.
The difference lies in their mechanisms. Methadone and buprenorphine are opioid agonists that activate brain receptors to some degree. This action reduces withdrawal and cravings while maintaining physiological tolerance to opioids. This maintained tolerance acts as a safety net—if someone relapses, they’re less likely to suffer a fatal overdose.
Naltrexone takes a different approach. As an opioid antagonist, it completely blocks opioid receptors without providing any opioid effect. This means people taking naltrexone lose their opioid tolerance over time. If they stop taking naltrexone and relapse, their previous dose could now be lethal. The FDA has issued warnings about this increased overdose risk.
| Medication | How It Works | What It Does | How It’s Given | Where Available |
|---|---|---|---|---|
| Methadone | Full opioid agonist that fully activates brain receptors with slow onset and long duration | Reduces cravings and withdrawal. Blocks euphoric effects of other opioids. Breaks cycle of illicit drug use | Daily oral dose (liquid, wafer, or pill) | Only through SAMHSA-certified Opioid Treatment Programs (OTPs) |
| Buprenorphine | Partial opioid agonist with “ceiling effect” that lowers overdose risk | Reduces cravings and withdrawal. Blocks effects of other opioids. Allows more normal feeling without high | Daily film/tablet under tongue; monthly/weekly injection; or 6-month implant | Can be prescribed in office settings by any clinician with appropriate DEA registration |
| Naltrexone | Opioid antagonist that completely blocks receptors with no opioid effect or abuse potential | Blocks euphoric effects so users can’t get high. May help reduce cravings | Daily oral pill or monthly injection | Can be prescribed by any licensed clinician. Patient must be opioid-free for 7-10 days first |
MAT for Alcohol Use Disorder
MAT also effectively treats alcohol use disorder using different FDA-approved medications:
Naltrexone: Also used for opioid addiction, it reduces heavy drinking by blocking alcohol’s euphoric effects.
Acamprosate: Helps prevent relapse in people who have stopped drinking by reducing cravings.
Disulfiram: Works as a deterrent by causing unpleasant physical reactions like nausea and flushing if alcohol is consumed.
The Critical Role of Counseling
While medications are MAT’s foundation, the most effective programs integrate them with counseling and behavioral therapies. In federally regulated Opioid Treatment Programs, counseling and psychosocial services are required components of care.
Why the Combination Works
The relationship between medication and counseling is synergistic, not merely additive. Addiction profoundly impairs brain function, making it difficult for people to regulate emotions, think rationally, or benefit from talk therapy while consumed by withdrawal and intense cravings.
MAT medications provide the neurobiological stability that makes effective counseling possible. By normalizing brain chemistry, medication creates physical and emotional equilibrium, freeing patients from addiction’s constant crisis state.
This stability becomes a prerequisite for therapeutic progress. Once stabilized, patients can better focus on recovery, engage in therapy, and develop skills needed for long-term success.
However, this doesn’t mean counseling should be a barrier to medication. Research increasingly supports “low-barrier” or “medication-first” approaches, especially in high-risk situations or areas with limited resources. The immediate goal is stabilizing patients with medication to prevent death, then connecting them to counseling as it becomes available.
Evidence-Based Therapies in MAT
Common therapeutic approaches include:
Cognitive-Behavioral Therapy (CBT): Helps people identify and change dysfunctional thought patterns and behaviors associated with substance use. Patients learn to recognize triggers, develop healthier coping strategies, and build supportive relationships.
Contingency Management: Uses positive reinforcement to encourage abstinence and treatment adherence. Patients earn tangible rewards like vouchers for meeting treatment goals such as negative drug tests or attending therapy sessions.
Group and Family Therapy: Group therapy provides community and peer support while reducing isolation and shame. Family therapy helps heal strained relationships, educates loved ones about addiction, and builds stronger support systems at home.
Motivational Enhancement Therapy: Designed to help people resolve ambivalence about treatment. Rather than being confrontational, therapists help patients find internal motivation to commit to life changes.
The Patient Journey Through MAT
MAT treatment typically follows structured phases designed to move people from active substance use toward long-term recovery. While every program is tailored to individual needs, the general process includes four main stages.
Assessment and Intake
Treatment begins with comprehensive assessment by medical providers and counselors. This evaluation covers substance use history, addiction severity, physical and mental health status, and social challenges like housing instability or legal issues.
The assessment is critical for developing personalized treatment plans, including determining which medication is most appropriate and what level of psychosocial support is needed.
Induction
Induction is the medically supervised start of medication. The goal is finding the correct initial dose that relieves withdrawal symptoms and reduces cravings without causing sedation or euphoric effects.
For buprenorphine patients, this phase has a crucial requirement: patients must arrive already in moderate opioid withdrawal. Because buprenorphine binds strongly to opioid receptors, taking it too soon can displace other opioids and trigger “precipitated withdrawal”—sudden, severe withdrawal symptoms.
When done correctly, patients typically feel significantly better within 30 to 45 minutes of their first dose. The induction phase usually lasts one to three days while providers adjust dosing.
Stabilization
Once the initial dose is established, patients enter stabilization, which can last several weeks or months. During this time, medication dosage may continue being fine-tuned to ensure cravings are eliminated and patients feel stable.
With physical symptoms under control, focus shifts toward psychosocial recovery. Patients work more intensively on treatment goals in counseling, learn to identify and manage triggers, and develop healthier coping skills.
Maintenance
The maintenance phase is MAT’s long-term stage, where people remain on stable, therapeutic medication doses while continuing counseling and recovery support services as needed.
Duration is highly individualized and determined by patients and their care teams. There’s no predetermined timeline. For some, MAT may last months or years; for others, it may be lifelong treatment, similar to managing other chronic diseases like diabetes or hypertension.
Research suggests treatment durations of at least 12 to 18 months are associated with the best long-term success rates.
Personal Stories of Recovery
Clinical data on MAT is powerful, but personal stories from people who found recovery through treatment offer equally compelling evidence of its effectiveness.
Michael, who was incarcerated for drug-related offenses, described his post-release experience: “It was the lifeline I didn’t know I needed. The cravings, which I thought would overpower me, were manageable. I could focus on mending bridges with my family and being a father again… Suboxone didn’t just treat my addiction; it gave me my life back.”
Natasha highlighted the integrated approach’s importance: “I don’t feel like if I was just on methadone alone I would have been able to get to where I am now. I had a great counselor because she helped me work through all of [my personal problems]. She helped me realize that I was more than just my addiction.”
A patient at a treatment center described the freedom that comes with stability: “When you can arrive daily to the clinic get your appropriate dose and know that you will feel normal for 24 hours and are no longer trapped spending all day finding the drug you need to avoid being sick, that feeling is priceless. You get your freedom back!”
Confronting Stigma and Myths
Despite overwhelming scientific consensus on its effectiveness, MAT remains controversial and widely misunderstood. Persistent myths, deep-seated stigma, and legitimate operational challenges continue hindering its implementation.
The “Substituting One Drug for Another” Myth
The most damaging misconception about MAT is that it simply trades one addiction for another. This belief is fundamentally incorrect. When prescribed and taken as directed, MAT medications like methadone and buprenorphine don’t produce euphoric “highs” associated with illicit drug use.
Instead, they work at controlled, therapeutic levels to stabilize and normalize brain circuits disrupted by addiction, allowing the brain to heal and function properly. The comparison to insulin for diabetes is helpful—both are medically necessary, life-saving medications used to manage chronic diseases.
Widespread Intervention Stigma
The “substitution” myth reflects a broader problem: stigma that targets not just people with addiction, but the medical treatment itself and professionals who provide it. Researchers have termed this “intervention stigma”—a unique form of bias that affects both patients and providers.
Public opinion surveys reveal the depth of this prejudice: one study found one-third of participants believed MAT substitutes addictions, and another third said they would refuse to see a physician who provides MAT.
This professional marginalization acts as a powerful disincentive for clinicians to get trained in or offer MAT. The stigma creates a cycle where effective treatment is underutilized partly because providers who could offer it are discouraged by their own professional communities.
Legitimate Operational Challenges
Beyond myths and stigma, MAT programs face real challenges, particularly around medication diversion. In some settings, especially correctional facilities, MAT medications can have contraband value and may be diverted for nonmedical use.
Treatment facilities have developed comprehensive strategies to address this risk. Anti-diversion protocols include dedicated staff for medication administration, requiring patients to consume liquids after taking doses, crushing or liquefying medications when appropriate, and direct observation during dosing.
The Access Gap: Why Gold Standard Treatment Remains Hard to Get
A central paradox defines MAT in America: it’s life-saving, cost-effective, “gold standard” treatment that remains massively underutilized. In 2022, only 25.1% of U.S. adults who needed OUD treatment received recommended medications. A larger portion (30%) received treatment without medications, and the largest group (42.7%) didn’t perceive they needed treatment at all.
Workforce Shortages
The nation faces a critical shortage of mental health and addiction specialists needed to provide MAT and associated therapies. This shortage is compounded by the “waivered but not prescribing” problem—even when authorized, many clinicians treat few or no patients.
The gap between authorization and practice reveals systemic flaws. Simply increasing eligible prescriber numbers is insufficient if supporting infrastructure is absent. Clinicians cite practical barriers: inadequate reimbursement rates, lack of time in busy practices, fear of DEA scrutiny, and critically, lack of institutional support and reliable counseling referral networks.
These shortages aren’t evenly distributed. Rural areas are hit hardest, with far fewer providers leading to longer travel times, prohibitive expenses, and long waitlists—all increasing relapse and death risk.
Systemic and Financial Barriers
Even where providers are available, systemic obstacles remain.
Regulatory Complexity: While eliminating the X-waiver was a landmark victory for buprenorphine access, methadone dispensing remains restricted to specialized Opioid Treatment Programs, creating significant access bottlenecks for one of the most effective medications.
Financial Barriers: Cost remains a major obstacle. Lack of health insurance, prohibitive out-of-pocket expenses, and poor reimbursement rates from insurers all limit patient access while disincentivizing provider participation.
Criminal Justice System Barriers
Access to MAT is particularly poor in jails and prisons, where fewer than half offer any form of medication despite proven benefits in reducing post-release deaths and recidivism. Standard cost and stigma barriers are compounded by security concerns and complex logistics of delivering medical care in correctional environments.
Policy Evolution: From Criminalization to Medical Treatment
American addiction treatment has slowly evolved from a law-enforcement approach toward a public health model. For most of the 20th century, following the Harrison Narcotics Act of 1914, it was effectively illegal for physicians to prescribe opioids to people with opioid addiction. This pushed addiction treatment out of mainstream medicine.
The Drug Addiction Treatment Act of 2000
A major turning point came with the Drug Addiction Treatment Act of 2000 (DATA 2000). This bipartisan legislation created a new paradigm, allowing qualified physicians to treat opioid use disorder with buprenorphine in medical offices for the first time in nearly a century.
The law established the “X-waiver” system requiring physicians to complete special training, obtain SAMHSA waivers, and receive special DEA numbers beginning with ‘X’. While DATA 2000 was monumental in expanding access, these requirements eventually became barriers themselves.
Eliminating the X-Waiver
In December 2022, Congress eliminated the DATA 2000 waiver requirement entirely. This historic change means any practitioner with standard DEA registration authority for Schedule III medications can now prescribe buprenorphine for opioid use disorder, as long as state law permits.
This single policy change dramatically increased the potential buprenorphine prescriber workforce overnight, removing major federal red tape.
The MATE Act
The same 2023 law enacted the Medication Access and Training Expansion (MATE) Act. This creates a one-time, 8-hour training requirement for all practitioners applying for new DEA registrations or renewing existing ones.
Effective June 27, 2023, any clinician prescribing controlled substances—from ADHD stimulants to anxiety benzodiazepines—must attest they’ve completed at least eight hours of training on substance use disorders. This policy aims to ensure baseline addiction education across all medical fields.
Finding MAT Treatment
Navigating the treatment system can be overwhelming, but federal agencies provide key resources to connect people with help.
Immediate Resources
SAMHSA National Helpline: 1-800-662-HELP (4357). This free, confidential, 24/7 service provides treatment referrals and information in English and Spanish for individuals and families facing substance use disorders.
988 Suicide & Crisis Lifeline: Call or text 988 anytime for emotional distress or suicidal crisis. This service is free, confidential, and available 24/7.
Finding Treatment Providers
FindTreatment.gov is the most comprehensive tool for locating treatment. This confidential, anonymous resource is managed by SAMHSA.
Using the Locator Tool:
- Enter your location (address, city, or ZIP code)
- Click “Sort & Filter” after searching
- Under “Facility Types,” select:
- Buprenorphine Practitioners: Office-based providers who prescribe buprenorphine
- Opioid Treatment Programs: Specialized clinics that dispense methadone
- Refine your search using filters for:
- Payment/insurance options (Medicaid, Medicare, private insurance, sliding fees)
- Type of care (outpatient, residential, hospital inpatient)
- Special programs (veterans, pregnant women, criminal justice clients)
Patient Rights
Federal law provides strong confidentiality protections for substance use disorder treatment records. 42 Code of Federal Regulations Part 2 offers stricter privacy protections than standard HIPAA requirements for other medical information.
The evidence for MAT as the gold standard for opioid use disorder is overwhelming. It saves lives, reduces crime, prevents disease transmission, and benefits society economically. The medications work by stabilizing brain chemistry disrupted by addiction, while counseling addresses psychological and social factors.
Yet despite this evidence, access remains limited by workforce shortages, systemic barriers, and persistent stigma. Recent policy changes like eliminating the X-waiver represent significant progress, but more work is needed to bridge the gap between those who need treatment and those who receive it.
Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.
